울트라제닉스제약(주)
US ˙ NasdaqGS ˙ US90400D1081

SecurityRARE / Ultragenyx Pharmaceutical Inc.
InstitutionXponance, Inc.
Latest Disclosed Ownership16,466 shares
Latest Disclosed Value $ 344,963
Xponance, Inc. reports 14.43% increase in ownership of RARE / Ultragenyx Pharmaceutical Inc.

On May 13, 2026 - Xponance, Inc. filed a 13F-HR form disclosing ownership of 16,466 shares of Ultragenyx Pharmaceutical Inc. (US:RARE) valued at $344,963 USD as of March 31, 2026. The entity filed a previous 13F-HR on February 12, 2026 disclosing 14,390 shares of Ultragenyx Pharmaceutical Inc.. This represents a change in shares of 14.43% during the quarter. The current value of the position is $383,822 USD.

Institutional Ownership: 13F and NPORT Filings

The Security and Class in the table below are shown exactly as filed by the investor. We do our best to track continuity of investments through acquisitions, and this will be reflected in the table as changes in names. In addition to descriptive data, performance of the investment is shown over time. To calculate quarterly performance, we first calculate cost basis of the shares purchased during the quarter, then use that to calculate gross profit. Quarterly return is Gross Profit / Starting Portfolio value.

Note that cost basis is calculated and stored in thousands, so small quarterly changes in shares frequently result in a cost basis of zero.

Upgrade to unlock premium data and export to Excel .

Disclosed Equity Positions (from 13F/NPORT Filings)
File
Date		 Effective
Date		Form Security Class ID Avg Price
Paid (Est)		 Reported
Shares		 ΔShares ΔShares
(%)		 Reported
Value
(x1000)		 ΔValue
(%)		 Alloc
(%)		 ΔAlloc ΔAlloc (%) Cost Basis
(x1000)		 Unrealized
Gain/Loss
(x1000)
2026-05-13 2026-03-31 13F ULTRAGENYX PHARMACEUTICAL IN COM 90400D108 16,466 2,076 14.43 345 4.24 0.0025
2026-02-12 2025-12-31 13F ULTRAGENYX PHARMACEUTICAL IN COM 90400D108 14,390 896 6.64 331 -18.52 0.0025
2025-11-12 2025-09-30 13F ULTRAGENYX PHARMACEUTICAL IN COM 90400D108 13,494 406 3.10 406 -14.74 0.0032
2025-08-14 2025-06-30 13F ULTRAGENYX PHARMACEUTICAL IN COM 90400D108 13,088 536 4.27 476 4.63 0.0040
2025-05-01 2025-03-31 13F ULTRAGENYX PHARMACEUTICAL IN COM 90400D108 12,552 347 2.84 455 -11.50 0.0044
2025-02-11 2024-12-31 13F ULTRAGENYX PHARMACEUTICAL IN COM 90400D108 12,205 940 8.34 513 -17.92 0.0047
2024-11-12 2024-09-30 13F ULTRAGENYX PHARMACEUTICAL IN COM 90400D108 11,265 174 1.57 626 37.36 0.0060
2024-08-14 2024-06-30 13F ULTRAGENYX PHARMACEUTICAL IN COM 90400D108 11,091 1,279 13.04 456 -0.66 0.0047
2024-05-13 2024-03-31 13F ULTRAGENYX PHARMACEUTICAL IN COM 90400D108 9,812 -350 -3.44 458 -5.57 0.0048
2024-01-31 2023-12-31 13F ULTRAGENYX PHARMACEUTICAL IN COM 90400D108 10,162 648 6.81 486 43.07 0.0058
2023-10-24 2023-09-30 13F ULTRAGENYX PHARMACEUTICAL IN COM 90400D108 9,514 53 0.56 339 -22.25 0.0046
2023-07-14 2023-06-30 13F ULTRAGENYX PHARMACEUTICAL IN COM 90400D108 9,461 1,824 23.88 436 42.48 0.0058
2023-04-18 2023-03-31 13F ULTRAGENYX PHARMACEUTICAL IN COM 90400D108 7,637 -78 -1.01 306 -14.29 0.0045
2023-01-24 2022-12-31 13F ULTRAGENYX PHARMACEUTICAL IN COM 90400D108 7,715 1,354 21.29 357 35.74 0.0058
2022-10-24 2022-09-30 13F ULTRAGENYX PHARMACEUTICAL IN COM 90400D108 6,361 -85 -1.32 263 -31.69 0.0051
2022-08-02 2022-06-30 13F ULTRAGENYX PHARMACEUTICAL IN COM 90400D108 6,446 750 13.17 385 -7.00 0.0077
2022-04-20 2022-03-31 13F ULTRAGENYX PHARMACEUTICAL IN COM 90400D108 5,696 -22 -0.38 414 -13.93 0.0069
2022-01-31 2021-12-31 13F ULTRAGENYX PHARMACEUTICAL IN COM 90400D108 5,718 97 1.73 481 -5.13 0.0075
2021-11-05 2021-09-30 13F ULTRAGENYX PHARMACEUTICAL IN COM 90400D108 5,621 -173 -2.99 507 -8.15 0.0096
2021-08-12 2021-06-30 13F ULTRAGENYX PHARMACEUTICAL IN COM 90400D108 5,794 5,794 552 0.0101
2021-05-10 2021-03-31 13F ULTRAGENYX PHARMACEUTICAL IN COM 90400D108 0 -1,838 -100.00 0 -100.00
2021-02-11 2020-12-31 13F ULTRAGENYX PHARMACEUTICAL IN COM 90400D108 1,838 1,838 254 0.0055
2020-10-26 2020-09-30 13F ULTRAGENYX PHARMACEUTICAL IN COM 90400D108 0 -2,627 -100.00 0 -100.00
2020-08-14 2020-06-30 13F ULTRAGENYX PHARMACEUTICAL IN COM 90400D108 2,627 2,627 205 0.0053
Legend
Shares
The total number of shares held by the institution at the end of the reporting period (the effective date). This is provided in the filing.
Value
The total value of the shares as of the effective date. This is provided in the filing.
Avg. Share Price
The weighted average share price of the shares held by the institution. We use FIFO accounting to determine this price
Class
This is the security class as indicated by the filer. There are a variety of values for this field. Common values include "EC" = equity common, "EP" - equity preferred
Allocation (%)
The percent of the institution's portfolio that this position represents. This is provided in NPORT filings. For 13F filings, we calculate it.
Change in Allocation
The change in allocation from the prior reporting period. This is calculated as current allocation - prior allocation.
Change in Allocation (%)
The percent change in allocation from the prior reporting period. This is calculated as (current allocation - prior allocation) / prior allocation.
Cost Basis
The total cost of the shares held. This is calculated as reported shares * avg. share price
Unrealized Gain/Loss
This is the market value of the position as of the effective date minus the cost basis.